Investors sceptical of Iluvien 36 month data in DMO
This article was originally published in Scrip
Executive Summary
While the much-anticipated 36-month data from Alimera Sciences' 956-patient Phase III FAME studies of Iluvien (fluocinolone acetonide intravitreal insert), which the company licensed from partner pSivida, demonstrated improvement in best corrected visual acuity (BCVA) of 15 letters from baseline in patients with diabetic macular oedema (DMO), the A and B trials failed individually to reach statistical significance.